en
Scientific article
English

Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study

ContributorsEUSTAR
Published inArthritis and rheumatism, vol. 63, no. 6, p. 1486-1496
Publication date2011
Abstract

To identify the determinants of antibody responses to adjuvanted split influenza A (H1N1) vaccines in patients with inflammatory rheumatic diseases.

Keywords
  • Adjuvants, Immunologic/adverse effects/therapeutic use
  • Adult
  • Antibodies, Viral/blood/immunology
  • Antibody Formation/immunology
  • Antirheumatic Agents/immunology
  • Arthritis, Rheumatoid/drug therapy/immunology
  • B-Lymphocytes/drug effects/immunology
  • Female
  • Hemagglutination Inhibition Tests
  • Humans
  • Influenza A Virus, H1N1 Subtype/immunology
  • Influenza Vaccines/adverse effects/immunology/therapeutic use
  • Male
  • Middle Aged
  • Spondylarthritis/drug therapy/immunology
  • Tumor Necrosis Factor-alpha/antagonists & inhibitors
Citation (ISO format)
EUSTAR. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. In: Arthritis and rheumatism, 2011, vol. 63, n° 6, p. 1486–1496. doi: 10.1002/art.30325
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0004-3591
735views
8downloads

Technical informations

Creation11/05/2012 11:54:00 AM
First validation11/05/2012 11:54:00 AM
Update time03/14/2023 5:49:04 PM
Status update03/14/2023 5:49:04 PM
Last indexation01/16/2024 12:44:42 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack